Merck to acquire a 16.5% stake in Personalis for $50m.

Merck, an advanced cancer genomics firm, agreed to acquire a 16.5% stake in Personalis, an advanced cancer genomics company, for $50m. “Individualized therapies have the potential to transform cancer care. A key focus for Personalis has been supporting Merck and Moderna in this important program and we are thrilled to extend the collaboration potentially through to treatment of cancer patients on a routine basis," Chris Hall, Personalis CEO.